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Background: Incidence of actinic keratosis (AKs) and nonmelanoma skin cancer appears to be increasing
worldwide due to increasing levels of ultraviolet radiation, lifestyle changes, and an aging population.
However, there is no population-based study focusing on AKs among Asian population. We aimed to
investigate the incidence, the treatment pattern, the medical utilization and the risk of malignant
neoplasm of the AKs patients in Taiwan.
Methods: We conducted a retrospective cohort study to investigate patients with AKs from 2003 to 2011
by using the National Health Insurance Research Database (NHIRD). The inclusion criteria were patients
who had at least two outpatient visits or one hospital admission of AK identiﬁed by dermatologist from
2004 to 2011. There were 35,933 patients with AKs (elderly [aged 65 years]: n ¼ 17,004; non-elderly
[aged <65 years]:18,929 patients).
Results: We found the incidence rate for AKs among elderly patients was higher than non-elderly. We
further found that there were 923 patients were identiﬁed skin malignant neoplasm after diagnosis of
AKs, and the incidence rate among elderly patients was higher than non-elderly (122.66 vs. 13.80 per
10,000 patient-year).
Conclusions: The AKs incidence rate was low in general population but particular high in elderly pop-
ulation in Taiwan. Our ﬁndings warrants further investigation into the relationship between actinic
keratosis and the nonmelanoma skin cancer (NMSC) in Asians and may affect the approach toward
primary prevention of NMSC in Asians with AKs.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Actinic keratosis (AKs) or solar keratosis is a cutaneous lesion
that results from the proliferation of atypical epidermal keratino-
cytes and also represents a step in the development of squamous
cell carcinoma (SCC)1,2. The diagnosis of AKs is more important for
the geriatric population than young individuals because not only
does the incidence of malignant skin lesions increase with age but
diagnosis of AKs also places the patients in a high-risk group for a
subsequent development of skin cancer3.
Several reports provide estimates on the growing numbers of
affected people and the economic burden of treatment4. In US, onethat they have non-potential
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es/by-nc-nd/4.0/).study based on data from the National Ambulatory Medical Care
Survey indicated that 5.2 million visits occurred annually for AK
during the periods of 2000 through 20035. A study in 2005 esti-
mated that AK affects more than 58 million people6. In northern
hemisphere populations, 11%e25% of adults have at least one AK,
compared with 40%e60% of adult Australians7,8. The prevalence
rate reported in England in 2000 was 15.4% in men and 5.9% in
women older than 40 years9. These rates increased to 34.1% and
18.2%, respectively, at 70 years of age, when prevalence was most
strongly related to 2 objective signs of sun exposure: solar elastosis
and lentigines9. Although these studies clearly demonstrate the
high prevalence of AK, there are no information focusing on the
epidemiology of actinic keratosis regarding among Asian popula-
tion. Updated investigation might be informative by providing a
more contemporary prevalence estimate.
Moreover, prior studies had suggested the worldwide incidence
of nonmelanoma skin cancer (basal cell carcinoma, and SCC) has
increased by 4%e8% per year since 196010. Meanwhile, a recent
South Korean research also pointed to a 2.14 fold increase in theicine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
The Incidence of Actinic Keratosis in Taiwan 219incidence of AKs in relation to the last decade of the last century11.
The AKs resulted in the growing numbers of affected people and
economic burden of treatment1. Early detection of skin cancer in
the pre-SCC stage with proper management may suppress the rise
in the incidence of SCC. In light of the above, AKs has become an
important public health problem. However, much of the data on the
epidemiology for AKs are derived from studies in light-skinned
Caucasians, and there is no national population-based study
focusing on AKs among a Chinese population.
We conducted a nationwide retrospective cohort study to
investigate the frequency of AKs diagnosis, the type of AKs treat-
ment, and themedical utilization of AKs patients in Taiwan. The risk
of malignant neoplasm in AKs patients was also evaluated. Updated
investigation in this study will be informative by providing a more
contemporary incidence estimate.
2. Materials and methods
2.1. Data source
We used the National Health Insurance Research Database
(NHIRD), which covered 99% of nearly 23 million people in Taiwan,
to conduct a retrospective cohort study during 2003e2011. The
NHIRD contained all the original claim data registration ﬁles and
original claims data for reimbursement.
2.2. Study population and cohort entry/exit date
To conduct a retrospective cohort study with a 9-year observa-
tion period (2003e2011). The inclusion criteria was patients who
had at least two outpatient visits or one hospital admission of AK
International Classiﬁcation of Disease-Clinical (ICD-9-CM) code
(702.0) identiﬁed by dermatologist. We deﬁned an individual's
entry date as the date of ﬁrst diagnosis of AK from 1 January 2004 to
31 December 2011. We excluded patients who developed skin
malignant neoplasm (ICD-9 code: 173) before the entry date. An
individual's cohort exit date would be the earlier of the ﬁrst diag-
nosis of skin malignant neoplasm (ICD-9 code: 173), or end of the
study period. A total of 35,933 patients with AKs were included in
this analysis.
2.3. Actinic keratosis treatment and study outcomes
For all study patients, procedural treatment and medical treat-
ment of AK during the whole period of follow-up after the entry
date were used, including cryotherapy, electro cauterization, exci-
sion of skin (facial skin, skin), and 5-ﬂuorouracil. All information on
procedural and medical treatment used by individual patients was
obtained from the NHIRD. The frequency of procedural treatment
use was deﬁned as number of outpatient visits within the whole
follow-up years. The outcome of interest is skin malignant
neoplasm (ICD-9 code: 173).
2.4. Statistical analysis
All statistical tests were two sided, with an alpha level of 0.05,
and the conﬁdence intervals (CIs) were 95%. Cox proportional
hazards model was used to evaluate whether AK is an important
risk factor for skin malignant neoplasm. We also adjusted for po-
tential confounders in the multivariable Cox models, including
patient demographics (age and gender), prior history of immuno-
suppressive drugs use, procedural and medical treatments during
the follow-up period. Data management and statistical analyses
were performed using SAS version 9.2 (SAS Institution Inc, Cary,
North Carolina) and Microsoft Excel 2013 software.3. Ethical approval
This study protocol was approved by Joint Institutional Review
Board established by Medical Research Ethics Foundation.
4. Results
There were 36,858 patients who were admitted for the ﬁrst time
with a primary diagnosis of AKs between 2004 and 2010. After
excluding 925 patients who had skin malignant neoplasm before
entry date, a total of 35,933 patients were included in the analysis of
procedural treatmentofAKsandskinmalignantneoplasm.Theoverall
incidence rate for AKs from 2004 to 2011 ranged from 1.66 to 2.18 per
ten thousand people. We found the incidence rate for AKs among
elderlypatients (range from7.22to10.59)washigher thannon-elderly
(range from 0.87 to 1.13) (Figure 1). The trend of decreasing incidence
of actinic keratosis in elderly patients was also found.
Of the 35,933 patients with AKs, 17,004 (47.3%) were elderly
patients, and 18,929 were non-elderly patients. At the baseline, we
found elderly patients had a higher proportion of male, lived in
southern Taiwan and others area, diagnosed in medical center or
regional or district hospital, used immunosuppressive drugs prior
to entry date, underwent cryotherapy, excision of facial skin, and
excision of skin (except face) surgery than non-elderly patients
(Table 1).
Nine hundred and twenty-three patients were identiﬁed with
skin malignant neoplasm after diagnosis of AKs, the overall inci-
dence rate of skin malignant neoplasm was 67.07 per 10,000
patient-year (95%CI, 62.88e71.53). Ninety-seven of the 18,929 non-
elderly patients and 826 of the 17,004 elderly patients were iden-
tiﬁed with skin malignant neoplasm after diagnosis of AKs (inci-
dence rates: 13.80 [95%CI, 11.31e16.84], and 122.66 [95%CI,
114.58e131.32] per 10,000 patient-year, respectively) (Table 2).
In the multivariable-adjusted Cox proportional hazards model,
we found the elderly (HR ¼ 8.85, 95%CI ¼ 7.06e11.08), female
(HR¼ 1.26, 95%CI¼ 1.11e1.44), residence in central area (HR¼ 1.33,
95%CI ¼ 1.08e1.64) or southern and others area (HR ¼ 1.51, 95%
CI ¼ 1.29e1.78) were signiﬁcant risk factors for skin malignant
neoplasm. Patients receiving treatments of cryotherapy (HR¼ 0.82,
95%CI ¼ 0.69e0.97) and electro cauterization (HR ¼ 0.56, 95%
CI ¼ 0.39e0.78) for AKs was associated with decreased risk of skin
malignant neoplasm (Table 3).
5. Discussion
The population-based estimates of the incidence of AKs are
scanty, even for Caucasians. In 1986, Marks evaluated the incidence
of AKs in 1040 Australian people aged more than 40 years and
found 60% of patients with AKs at baseline developed new lesions
during 12 months of follow-up, compared with only 19% of those
who were lesion-free on the ﬁrst examination12. Another study by
Nestor et al. reported the incidence of treated AKs was 446 ~ 11,045
per 10,000 people per year in two health maintenance organization
populations in South Florida, which many be the highest recorded
incidences in the world13. However, growing evidence had showed
precancerous and malignant skin alterations were relatively infre-
quent in Asians than Caucasians. A recent study of Japanese resi-
dents of Kauai, Hawaii, suggested that the average annual incidence
of SCC among Caucasians was ﬁve times higher and that of BCC was
14 times higher than Japanese14. Suzuki et al. conducted a recent
study evaluating 4867 Japanese residents of Hyogo and showed
that the incidence of AKs was approximately 20 per 10,000 people
per year. Compared with this study, the incidence of AKs in our
study is even much lower (2.27 ~ 3.75 vs. 8.6 ~ 29.1 per 10,000
people per year)14. Although the direct comparison of these values
Table 1
Baseline characteristics of actinic keratosis patients.
Total Non-elderly Elderly P-value
N % N % N %
35,933 100.0 18,929 52.7 17,004 47.3
Sex
Male 16,305 45.4 6709 35.5 9596 56.4 <0.001
Female 19,612 54.6 12,206 64.5 7406 43.6
Missing ¼ 16
Geographic area
Northern area 11,384 31.7 6555 34.6 4829 28.4 <0.001
Central area 7689 21.4 4884 25.8 2805 16.5
Southern & others area 16,860 46.9 7490 39.6 9370 55.1
Medical setting
Medical center 2887 8.0 571 3.0 2316 13.6 <0.001
Regional hospital 5802 16.2 1867 9.9 3935 23.1
District hospital 6943 19.3 3292 17.4 3651 21.5
Clinics and others 20,301 56.5 13,199 69.7 7102 41.8
Prior drug use
Immunosuppressive drugs 7643 21.3 3461 18.3 4182 24.6 <0.001
Treatment
Cryotherapy 21,935 61.0 7552 39.9 14,383 84.6 <0.001
Electro cauterization 3240 9.0 2483 13.1 757 4.5 <0.001
Excision of facial skin 1621 4.5 630 3.3 991 5.8 <0.001
Excision of skin (Except face) 2932 8.2 1306 6.9 1626 9.6 <0.001
Topical therapy 5-ﬂuorouracil 132 0.4 25 0.1 107 0.6 <0.001
Figure 1. Actinic keratosis. The incidence rate with stratiﬁcation by age.
Table 2
Incidence rates of skin malignant neoplasm during the follow-up.
Total Non-elderly Elderly
(n ¼ 35,933) (n ¼ 18,929) (n ¼ 17,004)
Skin malignant neoplasm
Follow-up, days (mean, SD) 1397.99 ± 824.06 1355.35 ± 809.84 1445.47 ± 837.09
Follow-up, patient-days 50,234,071 25,655,346 24,578,725
No(%) of new cases 923 (2.57%) 97 (0.51%) 826 (4.86%)
Incidence per 10,000 patient-year (95%CI) 67.07 (62.88e71.53) 13.80 (11.31e16.84) 122.66 (114.58e131.32)
C.-F. Hsieh et al.220
Table 3
Cox proportional hazards analysis of the risk for skin malignant neoplasm in actinic keratosis patients.
Univariate Multivariate
HR 95%CI P-value HR 95%CI P-value
Age
<65 1.00 1.00 <0.001
65 9.12 (7.39e11.255) <0.001 8.85 (7.06e11.08)
Sex
Male 1.00 0.001
Female 0.85 (0.75e0.97) 0.015 1.26 (1.11e1.44)
Geographic area
Northern area 1.00
Central area 1.09 (0.89e1.34) 0.392 1.33 (1.08e1.64) 0.007
Southern & others area 1.49 (1.27e1.74) <0.001 1.51 (1.29e1.78) <0.001
Prior drug use
Immunosuppressive drugs 1.19 (1.02e1.39) 0.023 1.03 (0.89e1.20) 0.663
Treatment
Cryotherapy 2.02 (1.73e2.36) <0.001 0.82 (0.69e0.97) 0.019
Electro cauterization 0.36 (0.25e0.51) <0.001 0.56 (0.39e0.78) 0.001
Excision of facial skin 5.71 (4.88e6.69) <0.001 4.59 (3.91e5.40) <0.001
Excision of skin (Except face) 1.85 (1.55e2.21) <0.001 1.45 (1.21e1.74) <0.001
Topical therapy 5-ﬂuorouracil 3.99 (2.39e6.64) <0.001 2.42 (1.44e4.05) 0.001
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resulting in inaccuracy, the ethnic differences in the incidence of
AKs remained noteworthy, probably suggesting an effect of skin
color.
Most of the previous research, mainly focusing on the preva-
lence, also showed the prevalence of AKs varied according to
various UV radiation levels in different geographic areas
(Australia > United States of America > Europe) and the studied
populations. Accumulating studies had shown that in northern
hemisphere populations, 11%e25% of adults have at least one AKs,
compared with 40%e60% of adult Australians, who live closer to the
equator and were thought to have the highest known rate of AKs in
the world9,15e18. In the USA, the prevalence is reported to be 11%e
25%7,18,19. With a prevalence of 40%e60%, the incidence is highest in
people living closest to the equator7,19. In UK, the prevalence rate
reported in England in 2000 was 15.4% in men and 5.9% in women
older than 40 years9. The South Wales Skin Cancer Study reported
an AKs prevalence of 23% in South Wales12.
Consistent with previous researches7,16,20, our study showed
that elderly patients have a higher risk of developing AKs compared
with non-elderly. Green et al. had evaluated the prevalence of AKs
in 2045 adults in Queensland and found that a higher rate of AKs
presented in adults between the ages of 60 and 69 than those aged
20e29 years (68 ~ 79% vs. 5 ~ 10%)16. Another cohort study of 1040
people over the age of 40 in North Central Victoria also revealed
that the mean age of individuals with AKs was signiﬁcantly higher
than in those without AKs (62 vs. 54 years)12.
Like other population-base study, our study also has several
limitations. The NHIRD did not contain some behavioral risk factors
and personal characteristics, such as ultraviolet index, occupational
or recreational sun exposure, sunscreens use, history of sunburn
episodes, place of birth, family history of skin malignancy. We
therefore could not adjust for the effects of these factors in the
development of AKs. Also, the treatments related with AKs might
not be speciﬁc for the treatment of actinic keratosis for some were
often applied for treatments of other common skin diseases which
may co-existed with or occur subsequently after the diagnosis of
actinic keratosis. However, we tried to include the treatment with
the diagnosis of AKs only to obtain more precise information.
Using a nationwide population base data in Taiwan, this study
demonstrates that the AKs incidence rate was low in the general
population but particular high in the elderly population in Taiwan.
The increasing trend was also found in the past decade. About 60%of patients received treatments and the cryotherapy was the major
therapy. Our ﬁndings warrants further investigation into the rela-
tionship between actinic keratosis and the NMSC in Asians andmay
affect the approach toward primary prevention of NMSC in Asians
with AKs.Funding/support statement
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